Compare Anheuser-Busch Inbev SA (BUD) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Heron Therapeutics Inc — how do they compare? Anheuser-Busch Inbev SA trades at $78.88 (market cap $153.45B), while Heron Therapeutics Inc trades at $0.43 (market cap $82.52M). The key difference: Anheuser-Busch Inbev SA is far larger — about 1859.5× Heron Therapeutics Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.7% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BUD | HRTX | |
|---|---|---|
Market Cap | $153.45B | $82.52M |
Sector | Consumer Staples | Health |
52-Week High | $85.09 | $2.04 |
52-Week Low | $57.10 | $0.39 |
Enterprise Value | $214.64B | $180.42M |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.33, down 0.35% with bearish technical signals. The company demonstrates solid fundamentals with consistent earnings beats, 11.9% net margin, and improving cash flow. Recent dividend payment of $1.17 and positive analyst sentiment with 57.8% buy ratings support the investment case. Premiumization strategy and digital expansion drive growth amid changing consumer preferences.
Outlook remains positive with $90.08 consensus price target offering 13.5% upside. Key risks include alcohol moderation trends and competitive pressures. Strong balance sheet with declining debt-to-asset ratio to 33.9% provides financial stability. Revenue growth expected to accelerate to $61B in 2026 with expanding margins.
HRTX trades at $0.42 with a slight 0.6% daily gain, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported Q1 2026 revenue of $151M with a net loss of $31M, continuing negative profitability trends. Recent news highlights patent litigation developments and management reaffirming full-year guidance despite quarterly misses.
While analyst consensus remains overwhelmingly bullish (95% buy ratings), fundamental challenges persist with negative earnings and cash flow. Investment opportunity exists if the company can achieve profitability turnaround, but risks include ongoing operational losses, competitive pressures in biotechnology, and patent litigation uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
